Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS) : A state-of-the-art review and implications for vaccine development
© 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC..
Background and Aims: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). MS results from an inflammatory process leading to the loss of neural tissue and increased disability over time. The role of Epstein Barr Virus (EBV), as one of the most common global viruses, in MS development has been the subject of several studies. However, many related questions are still unanswered. This study aimed to review the connection between MS and EBV and provide a quick outline of MS prevention using EBV vaccination.
Methods: For this narrative review, an extensive literature search using specific terms was conducted across online databases, including PubMed/Medline, Scopus, Web of Science, and Google Scholar, to identify pertinent studies.
Results: Several studies proved that almost 100% of people with MS showed a history of EBV infection, and there was an association between high titers of EBV antibodies and an increased risk of MS development. Various hypotheses are proposed for how EBV may contribute to MS directly and indirectly: (1) Molecular Mimicry, (2) Mistaken Self, (3) Bystander Damage, and (4) Autoreactive B cells infected with EBV.
Conclusion: Given the infectious nature of EBV and its ability to elude the immune system, EBV emerges as a strong candidate for being the underlying cause of MS. The development of an EBV vaccine holds promise for preventing MS; however, overcoming the challenge of creating a safe and efficacious vaccine presents a significant obstacle.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
Health science reports - 7(2024), 2 vom: 19. Feb., Seite e1898 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mohammadzamani, Mahtab [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
EBV vaccination |
|---|
| Anmerkungen: |
Date Revised 17.02.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1002/hsr2.1898 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM36851885X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM36851885X | ||
| 003 | DE-627 | ||
| 005 | 20240217232414.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240216s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/hsr2.1898 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1297.xml |
| 035 | |a (DE-627)NLM36851885X | ||
| 035 | |a (NLM)38361801 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mohammadzamani, Mahtab |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Insights into the interplay between Epstein-Barr virus (EBV) and multiple sclerosis (MS) |b A state-of-the-art review and implications for vaccine development |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 17.02.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © 2024 The Authors. Health Science Reports published by Wiley Periodicals LLC. | ||
| 520 | |a Background and Aims: Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS). MS results from an inflammatory process leading to the loss of neural tissue and increased disability over time. The role of Epstein Barr Virus (EBV), as one of the most common global viruses, in MS development has been the subject of several studies. However, many related questions are still unanswered. This study aimed to review the connection between MS and EBV and provide a quick outline of MS prevention using EBV vaccination | ||
| 520 | |a Methods: For this narrative review, an extensive literature search using specific terms was conducted across online databases, including PubMed/Medline, Scopus, Web of Science, and Google Scholar, to identify pertinent studies | ||
| 520 | |a Results: Several studies proved that almost 100% of people with MS showed a history of EBV infection, and there was an association between high titers of EBV antibodies and an increased risk of MS development. Various hypotheses are proposed for how EBV may contribute to MS directly and indirectly: (1) Molecular Mimicry, (2) Mistaken Self, (3) Bystander Damage, and (4) Autoreactive B cells infected with EBV | ||
| 520 | |a Conclusion: Given the infectious nature of EBV and its ability to elude the immune system, EBV emerges as a strong candidate for being the underlying cause of MS. The development of an EBV vaccine holds promise for preventing MS; however, overcoming the challenge of creating a safe and efficacious vaccine presents a significant obstacle | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a EBV vaccination | |
| 650 | 4 | |a Epstein‐Barr virus | |
| 650 | 4 | |a HHV‐6 | |
| 650 | 4 | |a human herpesvirus 6 | |
| 650 | 4 | |a multiple sclerosis | |
| 700 | 1 | |a Kazemzadeh, Kimia |e verfasserin |4 aut | |
| 700 | 1 | |a Chand, Swati |e verfasserin |4 aut | |
| 700 | 1 | |a Thapa, Sangharsha |e verfasserin |4 aut | |
| 700 | 1 | |a Ebrahimi, Narges |e verfasserin |4 aut | |
| 700 | 1 | |a Yazdan Panah, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Shaygannejad, Vahid |e verfasserin |4 aut | |
| 700 | 1 | |a Mirmosayyeb, Omid |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Health science reports |d 2018 |g 7(2024), 2 vom: 19. Feb., Seite e1898 |w (DE-627)NLM28665525X |x 2398-8835 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2024 |g number:2 |g day:19 |g month:02 |g pages:e1898 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/hsr2.1898 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2024 |e 2 |b 19 |c 02 |h e1898 | ||